Heterologous Prime-boost Immunization with AstraZeneca and Pfizer COVID-19 vaccines

Researchers from Germany have evaluated the eactogenicity profile of heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination among healthcare workers. The findings reveal that a 12-week interval regimen of heterologous vaccination is well-tolerated among participants. The study is currently published on a preprint server. In the entire study cohort, the reactogenicity data after the first vaccination with BNT162b2 or ChAdOx1 nCoV-19 were available for 178 and 148 participants, respectively.

Similarly, the reactogenicity data after homologous BNT162b2/BNT162b2 and heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccinations were available for 159 and 71 participants, respectively. In the heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination group, two doses of respective vaccines were administered at an interval of 12 weeks. Compared to heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination, ChAdOx1 nCoV-19 prime vaccination was associated with more frequent severe systemic reactions including fatigue, myalgia, headache, chills, and high fever.

The study findings reveal comparable reactogenicity for homologous BNT162b2/BNT162b2 and heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccinations. Among study participants, heterologous prime-boost vaccination exhibits a well-tolerated profile. Based on the study findings, the scientists recommend that immunizing people with the 1st dose of ChAdOx1 nCoV-19 vaccine and 2nd dose of BNT162b2 vaccine at an interval of 12 weeks can significantly reduce vaccine-associated reactogenicity.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref Link:

https://www.medrxiv.org/content/10.1101/2021.05.19.21257334v1

#Featured